BACKGROUND: Non-steroidal anti-inflammatory drugs are considered potentially harmful for patients with heart failure.
OBJECTIVE: To determine the prevalence of in-hospital NSAID use, their type, associated diagnosis and impact in clinical outcomes among patients with a diagnosis of heart failure.
METHODS: The University Health System Consortium Database was used to identify all first hospitalizations with an International Classification of Diseases-9 discharge diagnosis code of systolic heart failure as the primary diagnosis between January 1, 2011, and December 31st 2014.
RESULTS: Among 65,902 patients admitted for a primary diagnosis of SHF, 2675 (4.1%) were exposed to NSAID. The most frequent NSAID used was ibuprofen (51.63%), followed by ketorolac (29.38%) naproxen (8.07%) celecoxib (5.61%), and others. On multivariable analyses, the length of stay of patients exposed to NSAID was longer compared to non-exposed (OR: 4.67, p < 0.001, 95% CI 4.10–5.25), but differences in mortality were not statistically different (OR: 0.90, p = 0.476, 95% CI 0.69–1.19).
CONCLUSION: The use of NSAID in patients admitted with a primary diagnosis of systolic heart failure was low but was associated with longer length of stay. Further studies are needed to understand the impact of NSAID use in this patient population.
OngCKLirkPTanCHSeymourRA. An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5(1):19–34.
2.
ZhouYBoudreauDMFreedmanAN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014;23(1):43–50.
3.
LivingstoneCWrightJFyfeM. Hospital initiated NSAIDs and reducing CV risk. Prescriber. 2014;25(19):14–6.
4.
LaiwahACMactierRA. Antagonistic effect of non-steroidal anti-inflammatory drugs on frusemide-induced diuresis in cardiac failure. Br Med J (Clin Res Ed). 1981;283(6293):714.
5.
FowlerRWArnoldKG. Non-steroidal analgesics and anti-inflammatory agents. Br Med J (Clin Res Ed). 1983;287(6395):835.
6.
SchmidtMLambertsMOlsenAMFosbollENiessnerATamargoJRosanoGAgewallSKaskiJCKjeldsenKLewisBSTorp-PedersenC. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J. 2016;37(13):1015–23.
7.
ScottPAKingsleyGHScottDL. Non-steroidal anti-inflammatory drugs and cardiac failure: Meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008;10(11):1102–7.
8.
SchmidtMChristiansenCFMehnertFRothmanKJSorensenHT. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study. BMJ. 2011;343:d3450.
9.
PonikowskiPVoorsAAAnkerSDBuenoHClelandJGCoatsAJFalkVGonzalez-JuanateyJRHarjolaVPJankowskaEAJessupMLindeCNihoyannopoulosPParissisJTPieskeBRileyJPRosanoGMRuilopeLMRuschitzkaFRuttenFHvan der MeerP, Authors/Task Force M, Document R. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;37(27):2129–2200.
10.
YancyCWJessupMBozkurtBButlerJCaseyDEJrDraznerMHFonarowGCGeraciSAHorwichTJanuzziJLJohnsonMRKasperEKLevyWCMasoudiFAMcBridePEMcMurrayJJMitchellJEPetersonPNRiegelBSamFStevensonLWTangWHTsaiEJWilkoffBL, American College of Cardiology F, American Heart Association Task Force on Practice G. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147–239.
11.
FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes 2014 [cited 2016 08-04-2016]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm
12.
GrecoGShiWMichlerREMeltzerDOAilawadiGHohmannSFThouraniVHArgenzianoMAlexanderJHSankovicKGuptaLBlackstoneEHAckerMARussoMJLeeABurksSGGelijnsACBagiellaEMoskowitzAJGardnerTJ. Costs associated with health care-associated infections in cardiac surgery. Journal of the American College of Cardiology. 2015;65(1):15–23.
13.
SaczynskiJSAndradeSEHarroldLRTjiaJCutronaSLDoddKSGoldbergRJGurwitzJH. A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):129–40.
14.
AllenLASmoyer TomicKESmithDMWilsonKLAgodoaI. Rates and predictors of 30-day readmission among commercially insured and Medicaid-enrolled patients hospitalized with systolic heart failure. Circ Heart Fail. 2012;5(6):672–9.
15.
HuntSA, American College of C, American Heart Association Task Force on Practice G. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Journal of the American College of Cardiology. 2005;46(6):e1–82.
16.
PageRL2ndO’BryantCLChengDDowTJKyBSteinCMSpencerAPTruppRJLindenfeldJ, American Heart Association Clinical P, Heart F, Transplantation Committees of the Council on Clinical C, Council on Cardiovascular S, Anesthesia, Council on C, Stroke N, Council on Quality of C, Outcomes R. Drugs that may cause or exacerbate heart failure: A scientific statement from the American heart association. Circulation. 2016;134(6):e32–69.
17.
ArfeAScottiLVaras-LorenzoCNicotraFZambonAKollhorstBSchinkTGarbeEHeringsRStraatmanHSchadeRVillaMLucchiSValkhoffVRomioSThiessardFSchuemieMParienteASturkenboomMCorraoG, Safety of Non-steroidal Anti-inflammatory Drugs Project C. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: Nested case-control study. BMJ. 2016;354:i4857.
18.
CannonCPCurtisSPFitzGeraldGAKrumHKaurABologneseJAReicinASBombardierCWeinblattMEvan der HeijdeDErdmannELaineLCommitteeMS. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006;368(9549):1771–81.
19.
NissenSEYeomansNDSolomonDHLüscherTFLibbyPHusniMEGrahamDYBorerJSWisniewskiLMWolskiKEWangQMenonVRuschitzkaFGaffneyMBeckermanBBergerMFBaoWLincoffAM. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New England Journal of Medicine0(0):null.
20.
BeckerMCWangTHWisniewskiLWolskiKLibbyPLuscherTFBorerJSMascetteAMHusniMESolomonDHGrahamDYYeomansNDKrumHRuschitzkaFLincoffAMNissenSE, Investigators P. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606–12.
21.
EvangelistaLSSackettEDracupK. Pain and heart failure: Unrecognized and untreated. Eur J Cardiovasc Nurs. 2009;8(3):169–73.
22.
DoshiDBen-YehudaOBonafedeMJosephyNKarmpaliotisDParikhMAMosesJWStoneGWLeonMBSchwartzAKirtaneAJ. Underutilization of coronary artery disease testing among patients hospitalized with new-onset heart failure. Journal of the American College of Cardiology. 2016;68(5):450–8.
23.
LiQGlynnRJDreyerNALiuJMogunHSetoguchiS. Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiol Drug Saf. 2011;20(7):700–8.
